Workflow
血管介入类产品
icon
Search documents
身价300亿,威海首富收获第四个IPO
投中网· 2025-05-28 06:35
以下文章来源于东四十条资本 ,作者蒲凡 东四十条资本 . 聚焦股权投资行业人物、事件、数据、研究、政策解读,提供专业视角和深度洞见 | 创投圈有趣的灵魂 将投中网设为"星标⭐",第一时间收获最新推送 一轮融资就搞定的IPO。 作者丨 蒲凡 来源丨 东四十条资本 威海"首富"陈学利拿下了他的第四家上市公司。 近日,山东威高血液净化制品股份有限公司(以下简称"威高血净")正式在上海证券交易所主板挂牌,IPO发行价格为每股 26.50元人民币,上市首日开盘价上涨88.64%报49.99元,市值一度突破200亿元,远高于上市递表时的目标估值。 虽然上 市后持续股价持续下挫,但市值仍然接近150亿元。 3年前,威高血净曾经申报过港股IPO,后于2023年底改道A股,当时IPO目标估值为135.1亿元,现在无疑算是超额完成了 任务。根据招股书显示,威高血净已经成为了血液透析器材领域内当之无愧的龙头老大,无论统计整个国内血液透析器领 域,还是细分到血液透析管路领域,市场份额均超过32%。 威高血净"系出名门"。在本次申报IPO之前,威高血净的母公司威高集团旗下已经拥有了两家上市公司和一家准上市公司, 分别是从一次性输液器起 ...
国科恒泰(301370) - 2025年5月13日投资者关系活动记录表
2025-05-13 10:04
Group 1: Business Competitiveness and Strategy - The company's core competitive advantages include warehousing logistics, information systems, professional teams, and integrated management capabilities, which create barriers in upstream production, inventory scale, and terminal medical institution resources [1] - Currently, there are no acquisition plans, but the company acknowledges that mergers and acquisitions play a significant role in strengthening and expanding operations [2] Group 2: Growth Drivers and Market Trends - The demand for vascular intervention products is driven by the aging population, with a significant positive correlation between the prevalence of cardiovascular diseases and age [2] - The company aims to expand its product offerings beyond vascular intervention and orthopedics, focusing on equipment and IVD categories [2] Group 3: Performance Goals and Risk Management - The management is committed to daily operations and exploring new development paths to uncover new profit growth points, aiming for better performance to reward investors [2] - The company plans to adopt a diversified supply chain strategy to mitigate trade risks and reduce reliance on single sources or brands, while maintaining partnerships with large multinational companies [2]